Valicenti Advisory Services’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.95M Buy
36,839
+2,354
+7% +$392K 1.12% 26
2026
Q2
$6.54M Buy
34,485
+3,300
+11% +$621K 1.23% 24
2026
Q1
$6.15M Buy
31,185
+287
+0.9% +$55.3K 1.34% 23
2025
Q4
$5.68M Buy
30,898
+550
+2% +$96.5K 1.19% 26
2025
Q3
$4.66M Sell
30,348
-7,647
-20% -$1.16M 1% 29
2025
Q2
$5.31M Buy
37,995
+255
+0.7% +$35.7K 1.24% 25
2025
Q1
$5.55M Buy
37,740
+47
+0.1% +$6.8K 1.43% 22
2024
Q4
$4.94M Sell
37,693
-209
-0.6% -$29.3K 1.23% 26
2024
Q3
$5.91M Buy
37,902
+635
+2% +$103K 1.52% 25
2024
Q2
$5.81M Sell
37,267
-1,595
-4% -$240K 1.56% 19
2024
Q1
$5.27M Buy
+38,862
New +$5.15M 1.47% 23

Other funds holding AZN

Valicenti Advisory Services's AZN Position: Q3 2026 in Review

Valicenti Advisory Services increased its AstraZeneca (AZN) stake by 6.8% in Q3 2026, buying an estimated $392K and bringing the position to 36,839 shares worth $5.95M. The position accounts for 1.12% of the portfolio, ranked #26.

Valicenti Advisory Services first reported a position in AZN in Q1 2024 and has held it in 11 quarters since. The position peaked at $6.54M in Q2 2026. 441 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Valicenti Advisory Services held 36,839 shares of AstraZeneca worth $5.95M as of Q3 2026.
  • Valicenti Advisory Services bought 2,354 AstraZeneca shares in Q3 2026, an estimated $392K.
  • AstraZeneca made up 1.12% of Valicenti Advisory Services's portfolio in Q3 2026, its #26 holding.
  • Valicenti Advisory Services first reported a position in AstraZeneca in Q1 2024 and has held it in 11 quarters since.
  • Valicenti Advisory Services's AstraZeneca position peaked at $6.54M in Q2 2026.
  • 441 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Valicenti Advisory Services's 13F filing for Q3 2026, filed 23 Oct 2026.